We are organizing a workshop on the definition of meaningful outcomes for hematological malignancies at 23 and 24 November 2017 at Takeda. Takeda is on of the 52 HARMONY Alliance Partners.
Together with our 60 invited stakeholder relations we would like to brainstorm, exchange and generate ideas regarding on outcomes relevant for all stakeholders. Next to plenary session with focus on methodologies and learnings from others, break-out sessions are organized on diseases (multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS), and pediatric Hematologic Malignancies).
Objective: Brainstorm, exchange and generate ideas regarding a list of outcomes relevant for all stakeholders. Generate a list of outcomes by HM and a list of standard core outcomes valid for all HMs valued by all stakeholders participating in the workshop, for later validation
Brief description: The agenda of this workshop focuses on outcomes definition, integration between the HARMONY Work Packages 2 and 6 and determining priorities for the next few months. The workshop will follow up on the 2nd HARMONY General Assembly of October in Berlin and will be focus on five disease areas (MM, MDs &AML, CLL &NHL, ALL, childhood HM).
Event registration is by invitation only. Would you like to know more about this HARMONY Workshop send us an email.
Are you interested in starting your research project while using big data analyses from HARMONY? Join our Alliance and become an Associate Member. Please contact the Coordination Office at firstname.lastname@example.org.